Continuous Glucose Monitoring Cuts Readmission Risks

A new prospective study has found that initiating continuous glucose monitoring (CGM) at the point of hospital discharge is associated with significantly improved glycemic control and may halve the risk of hospital readmission for patients with type 2 diabetes. The research, published in Journal of the Endocrine Society , suggests that providing patients with real-time data during the high-risk transition from inpatient to home care is both feasible and safe. This clinical “bridge” addresses a long-standing gap in diabetes management where patients often struggle to maintain the stability achieved under professional supervision once they return to their daily routines. The study, “ Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes ,” conducted by researchers at The Ohio State University Wexner Medical Center, focused on 108 hospitalized adults with poorly controlled type 2 diabetes (HbA1c > 8.0%) who required basal insulin therapy. By equipping participants with a Dexcom G6 CGM system upon leaving the hospital, clinicians were able to monitor their transition over a 12-week period. The results were striking: Average HbA1c levels plummeted from an initial median 12% to 8.2% by the conclusion of the study. This rapid improvement underscores the transformative power of real-time biofeedback in patient self-management. As healthcare systems look for ways to reduce the burden of chronic disease management, these findings highlight CGM as a potential standard of care for the transition period. By providing a digital safety net, hospitals can empower patients to manage their diabetes more effectively, ensuring that the progress made during a hospital stay is not lost once the patient returns home. This transition period is particularly critical because the weeks following hospital discharge are often fraught with medication errors and fluctuating glucose levels. Traditionally, initiation of CGM is deferred to the outpatient setting and patients rely on intermittent finger-stick tests, which offer only a disconnected snapshot of their metabolic state. In contrast, CGM provides a continuous stream of data, allowing for immediate adjustments to insulin dosing and diet. By visualizing how specific meals or activities impact their blood sugar, patients can make informed decisions in real-time, effectively preventing the dangerous “peaks and valleys” that often lead to re-hospitalization. The data revealed that patients who consistently utilized the CGM technology were significantly more stable than those who did not. Most notably, the readmission rate within the 12-week follow-up period was just 23% for those with consistent CGM data, compared to 50% for those without. Furthermore, patients equipped with the device were nearly eight times more likely to follow up with an outpatient endocrinologist (49% vs. 6%), suggesting either a need for ongoing diabetes-focused care in CGM users or potentially that CGM promotes better engagement with the healthcare team. “Initiating CGM at hospital discharge was feasible, safe, and associated with significant glycemic improvement,” the researchers concluded. The study noted that time in range (TIR) — the percentage of time a patient’s glucose stays between 70 and 180 mg/dL—increased steadily throughout the 12 weeks, moving from 37% to 43%. This improvement, if sustained, is a vital indicator of reduced long-term complications, such as nerve damage and kidney disease. As healthcare systems look for ways to reduce the burden of chronic disease management, these findings highlight CGM as a potential standard of care for the transition period. By providing a digital safety net, hospitals can empower patients to manage their diabetes more effectively, ensuring that the progress made during a hospital stay is not lost once the patient returns home. The post Continuous Glucose Monitoring Cuts Readmission Risks appeared first on Endocrine News .